Eiger Gets OK On Ch. 11 Drug Sale After Tripling Initial Bid
A Texas bankruptcy judge on Wednesday approved Eiger BioPharmaceuticals' $35.1 million sale of its Avexitide product, after the drug company more than tripled an initial bid for the metabolic-disease treatment during...To view the full article, register now.
Already a subscriber? Click here to view full article